Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07234955

Minimally Invasive Surgery For Patients With Spontaneous Deep Intracerebral Hemorrhage

This observational cohort study evaluates the safety and effectiveness of minimally invasive surgery (MIS) compared with standard medical management in adults with spontaneous deep intracerebral hemorrhage. Consecutive patients admitted to People's Hospital 115 and Tam Anh General Hospital will be enrolled within 72 hours of onset. Clinical and imaging data will be collected prospectively, and outcomes including survival and functional status will be assessed through 180 days.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

People's Hospital 115

Ho Chi Minh City, Ho Chi Minh, 700000, Vietnam

Location status: Recruiting

Location contact

Huy Q Huynh, MD

CONTACT

[email protected]

+84 943054927

About this study

Spontaneous deep intracerebral hemorrhage (ICH) is associated with high early mortality and long-term disability. Conventional craniotomy has not consistently improved functional outcomes, while medical management alone often results in poor prognosis. Minimally invasive surgery (MIS), including parafascicular approaches guided by neuronavigation, is designed to evacuate hematomas with reduced disruption of critical white-matter tracts. Evidence supporting MIS is more robust in lobar ICH, whereas data for basal ganglia hemorrhage remain limited. Furthermore, most prior studies restricted surgical intervention to within 24 hours from onset, leaving uncertainty regarding potential benefit when performed between 24 and 72 hours.

This prospective, multicenter, observational cohort study is conducted at People's Hospital 115 and Tam Anh General Hospital. Consecutive patients admitted with spontaneous basal ganglia ICH are enrolled within 72 hours of onset. Decisions regarding MIS, including whether to operate and the timing of surgery, are made by treating clinical teams in routine practice. The study does not assign interventions but documents real-world management and outcomes.

Data are captured prospectively using standardized CRFs and electronic CRFs. Information includes demographics, comorbidities, presenting neurological status, laboratory and imaging findings, details of MIS when performed, intensive care and hospital course, and follow-up assessments through 180 days. The primary endpoint is functional outcome at 180 days, while safety endpoints include mortality and treatment-related complications. Analyses are planned using prespecified multivariable approaches to account for confounding by indication. Additional subgroup analyses will assess outcomes by timing of MIS (0-24 vs 24-72 hours) and other clinically relevant variables.

By focusing on basal ganglia hemorrhage in contemporary Vietnamese stroke centers, this study is intended to generate real-world evidence on the effectiveness and safety of MIS in deep ICH and inform selection criteria and timing for future interventional trials.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 to 80 years
  • Spontaneous basal ganglia intracerebral hemorrhage confirmed by non-contrast CT scan
  • Hematoma volume 30-80 mL (ABC/2 method)
  • Time from onset/last known well ≤ 72 hours
  • Glasgow Coma Scale (GCS) score 5-14 at admission
  • Pre-stroke modified Rankin Scale (mRS) score 0-1

Exclusion criteria

  • Secondary intracerebral hemorrhage due to trauma, tumor, vascular malformation, aneurysm, or hemorrhagic transformation of ischemic stroke
  • Infratentorial hemorrhage (brainstem or cerebellum)
  • Primary thalamic hemorrhage
  • Extensive intraventricular hemorrhage (>50% of one lateral ventricle)
  • NIHSS < 5 at admission
  • Bilateral fixed dilated pupils without light reflex
  • Decerebrate posture
  • Platelet count < 75,000/µL
  • INR > 1.4 after correction
  • Ongoing anticoagulation that cannot be rapidly reversed
  • Indication for long-term anticoagulation within 5 days of onset
  • End-stage renal disease
  • End-stage liver disease
  • Presence of mechanical heart valve
  • Any comorbidity with life expectancy < 6 months
  • Patient or legal representative unwilling or unable to provide written informed consent

Treatment and study plan

Primary outcomes

  1. Primary Outcome Measure 1 - Efficacy: Functional Outcome by Modified Rankin Scale (mRS)

    Time frame: 180 days after intracerebral hemorrhage

    Proportion of participants achieving favorable functional outcome defined as mRS 0-3.

    Unit of Measure: Percentage of participants

  2. Primary Outcome Measure 2 - Efficacy: Functional Outcome by Utility-Weighted mRS (UW-mRS)

    Time frame: 180 days after intracerebral hemorrhage

    Mean UW-mRS score at 180 days after intracerebral hemorrhage. The UW-mRS is a continuous, utility-weighted measure of functional outcome ranging from 0 (death) to 1 (no symptoms).

    Unit of Measure: Score (0-1 scale)

  3. Primary Outcome Measure 3 - Safety: All-Cause Mortality

    Time frame: 30 days after intracerebral hemorrhage

    Number of participants who die from any cause within 30 days after intracerebral hemorrhage.

    Unit of Measure: Percentage of participants

  4. Primary Outcome Measure 4 - Safety: Procedure-Related Complications

    Time frame: Within hospitalization and up to 30 days after intracerebral hemorrhage

    Incidence of major complications related to minimally invasive surgery or medical management, including but not limited to rebleeding, infection, seizures, or other serious adverse events as judged by the investigators.

    Unit of Measure: Number of participants with complications

Secondary outcomes

  1. Secondary Outcome Measure 1: Functional Outcome by Timing of MIS (0-24 Hours vs 24-72 Hours)

    Time frame: 180 days after intracerebral hemorrhage

    Proportion of participants achieving favorable functional outcome (mRS 0-3) at 180 days, compared between patients undergoing minimally invasive surgery (MIS) within 0-24 hours and those undergoing MIS within 24-72 hours after intracerebral hemorrhage.

    Unit of Measure: Percentage of participants

  2. Secondary Outcome Measure 2: All-Cause Mortality at 30 Days by Timing of MIS (0-24 Hours vs 24-72 Hours)

    Time frame: 30 days after intracerebral hemorrhage

    All-cause mortality within 30 days, compared between participants undergoing MIS within 0-24 hours versus 24-72 hours after intracerebral hemorrhage.

    Unit of Measure: Percentage of participants.

  3. Secondary Outcome Measure 3: Procedure-Related Complications by Timing of MIS (0-24 Hours vs 24-72 Hours)

    Time frame: Within hospitalization and up to 30 days after intracerebral hemorrhage

    Incidence of major procedure-related complications (e.g., postoperative rebleeding, surgical site infection, CSF leak, clinically significant seizures) during index hospitalization and through 30 days, compared between participants undergoing MIS within 0-24 hours versus 24-72 hours.

    Unit of Measure: Number of participants with ≥1 complication

Study contacts

Contact information is provided by the study sponsor or research team.

Huy Q Huynh, MD

CONTACT

[email protected]

+84 943054927

Sponsors and collaborators

Lead sponsor

Huynh Quoc Huy

Other Gov

Registry information

Official study title

Evaluation Of The Efficacy And Safety Of Minimally Invasive Surgery In Patients With Spontaneous Deep Intracerebral Hemorrhage

Acronym: MISDIH

Important dates

Study start
2025
Primary completion
2028
Study completion
2028
First posted
Nov 19, 2025
Registry last updated
Nov 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.